Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review

SummaryValproic acid (VPA; 2-n-propylpentanoic acid) is widely used as a major drug in the treatment of epilepsy and in the control of several types of seizures. Being a simple fatty acid, VPA is a substrate for the fatty acid β-oxidation (FAO) pathway, which takes place primarily in mitochondria. The toxicity of valproate has long been considered to be due primarily to its interference with mitochondrial β-oxidation. The metabolism of the drug, its effects on enzymes of FAO and their cofactors such as CoA and/or carnitine will be reviewed. The cumulative consequences of VPA therapy in inborn errors of metabolism (IEMs) and the importance of recognizing an underlying IEM in cases of VPA-induced steatosis and acute liver toxicity are two different concepts that will be emphasized.

[1]  T. Baillie,et al.  Metabolic activation of unsaturated derivatives of valproic acid: role of microsomal versus mitochondrial enzyme systems , 1992 .

[2]  T. Bohan,et al.  Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[3]  D. Turnbull,et al.  The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. , 1983, Biochemical pharmacology.

[4]  D. Cotariu,et al.  Valproic acid and the liver. , 1988, Clinical chemistry.

[5]  G. Zaccara,et al.  Clinical Pharmacokinetics of Valproic Acid — 1988 , 1988, Clinical pharmacokinetics.

[6]  W. Loscher,et al.  Identification of Metabolites of Valproic Acid in Serum of Humans, Dog, Rat, and Mouse , 1978, Epilepsia.

[7]  A. Bröer,et al.  Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. , 2000, American journal of physiology. Renal physiology.

[8]  S. Kolvraa,et al.  The occurrence of C6--C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate. , 1980, Biochemical medicine.

[9]  J. de Jersey,et al.  Studies on the reactivity of acyl glucuronides--III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. , 1992, Biochemical pharmacology.

[10]  W. Löscher,et al.  Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings , 1981, Neuropharmacology.

[11]  R. Wanders,et al.  Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites. , 2001, Analytical biochemistry.

[12]  H. Nau,et al.  Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. , 1981, The Journal of pharmacology and experimental therapeutics.

[13]  L. Benet,et al.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? , 1992, Drug metabolism reviews.

[14]  S. Servidei,et al.  Late onset lipid storage myopathy due to multiple acyl CoA dehydrogenase deficiency triggered by valproate , 1991, Neuromuscular Disorders.

[15]  M. Sztajnkrycer.  Valproic Acid Toxicity: Overview and Management , 2002, Journal of toxicology. Clinical toxicology.

[16]  K Farrell,et al.  Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[17]  M. Nagao,et al.  Influence of valproic acid on the expression of various acyl‐CoA dehydrogenases in rats , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[18]  R. Hehlmann,et al.  Fatal Liver Failure Associated with Valproate Therapy in a Patient with Friedreich's Disease: Review of Valproate Hepatotoxicity in Adults , 1999, Epilepsia.

[19]  H. Nau,et al.  Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation , 1996, FEBS letters.

[20]  F. Glocker,et al.  Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency , 2001, Neuromuscular Disorders.

[21]  Robert A. Harris,et al.  Influence of valproic acid on hepatic carbohydrate and lipid metabolism. , 1983, Archives of biochemistry and biophysics.

[22]  K. Moore,et al.  Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-fed animals. , 1988, The International journal of biochemistry.

[23]  I. T. de Almeida,et al.  Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[24]  I. T. de Almeida,et al.  Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids. , 2007, Biochimica et biophysica acta.

[25]  D. Shen,et al.  Absorption, distribution, and excretion , 1999 .

[26]  M. Leão.  Valproate as a Cause of Hyperammonemia in Heterozygotes With ornithine-transcarbamylase Deficiency , 1995, Neurology.

[27]  T. Bohan,et al.  l‐Carnitine Supplementation in Childhood Epilepsy: Current Perspectives , 1998, Epilepsia.

[28]  T. Bohan,et al.  Effect of l-carnitine treatment for valproate-induced hepatotoxicity , 2001, Neurology.

[29]  D. Pessayre,et al.  Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. , 1997, Journal of hepatology.

[30]  N. Reynolds,et al.  Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy , 1981, Neurology.

[31]  G. Carraz,et al.  [Pharmacodynamic properties of N-dipropylacetic acid]. , 1963, Therapie.

[32]  F. Abbott,et al.  Chemistry and biotransformation , 1999 .

[33]  I. Tein,et al.  Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. , 1994, Biochemical and biophysical research communications.

[34]  M. Bailey,et al.  Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. , 1996, Chemical research in toxicology.

[35]  D. Pessayre,et al.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. , 2006, Mitochondrion.

[36]  M. Hjelm,et al.  Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. , 1986, British medical journal.

[37]  S. Shorvon.  Epidemiology, classification, natural history, and genetics of epilepsy , 1990, The Lancet.

[38]  T. Baillie,et al.  Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[39]  T. Woolf.  Handbook of Drug Metabolism , 1999 .

[40]  G. Avanzini,et al.  Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients , 1995, Clinical pharmacokinetics.

[41]  T. Kuhara,et al.  Metabolism of branched medium chain length fatty acid. II--beta-oxidation of sodium dipropylacetate in rats. , 1974, Biomedical mass spectrometry.

[42]  C. Stanley,et al.  Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome. , 1988, The Journal of clinical investigation.

[43]  D. Pessayre,et al.  Hepatotoxicity due to mitochondrial dysfunction , 2004, Cell Biology and Toxicology.

[44]  W. Löscher.  Basic Pharmacology of Valproate , 2002 .

[45]  A. Munnich,et al.  Valproate-induced hepatic failure in a case of cytochromec oxidase deficiency , 1994, European Journal of Pediatrics.

[46]  Thomas K. H. Chang,et al.  Oxidative Stress as a Mechanism of Valproic Acid-Associated Hepatotoxicity , 2006, Drug metabolism reviews.

[47]  M. Gris,et al.  Science review: Carnitine in the treatment of valproic acid-induced toxicity – what is the evidence? , 2005, Critical care.

[48]  T. Baillie,et al.  Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[49]  U. Stephani,et al.  Severe Hepatotoxicity During Valproate Therapy: An Update and Report of Eight New Fatalities , 1994, Epilepsia.

[50]  J. Nezu,et al.  Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. , 1999, The Journal of pharmacology and experimental therapeutics.

[51]  A. Kamiya,et al.  Urinary metabolites of valproic acid in epileptic patients. , 1998, Biological & pharmaceutical bulletin.

[52]  Paul B Watkins,et al.  Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.

[53]  C. Gau,et al.  Interaction between Anticonvulsants and Human Placental Carnitine Transporter , 2004, Epilepsia.

[54]  R. Gugler,et al.  Clinical Pharmacokinetics of Valproic Acid , 1980, Clinical pharmacokinetics.

[55]  F. Dreifuss,et al.  Valproic acid hepatic fatalities. III. U.S. experience since 1986 , 1996, Neurology.

[56]  J. Sarles,et al.  Inappropriate liver transplantation in a child with Alpers–Huttenlocher syndrome misdiagnosed as valproate‐induced acute liver failure , 2000, Pediatric transplantation.

[57]  N. Gerber,et al.  Reye-like syndrome associated with valproic acid therapy. , 1979, The Journal of pediatrics.

[58]  T. Baillie,et al.  Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4‐ene‐valproate, a hepatotoxic metabolite of valproic acid , 1990, Clinical pharmacology and therapeutics.

[59]  G. Donnan,et al.  Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy. , 1981, Neurology.

[60]  Devane Cl.  Pharmacokinetics, drug interactions, and tolerability of valproate. , 2003, Psychopharmacology bulletin.

[61]  W. Löscher,et al.  Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. , 1982, The Journal of pharmacology and experimental therapeutics.

[62]  G. Granneman,et al.  The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism , 1984, Hepatology.

[63]  R. Wanders,et al.  Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. , 2002, The Biochemical journal.

[64]  C. Nemeroff,et al.  Pharmacology of valproate. , 2003, Psychopharmacology bulletin.

[65]  J. Fong,et al.  On the rate-determining step of fatty acid oxidation in heart. Inhibition of fatty acid oxidation by 4-pentenoic acid. , 1978, The Journal of biological chemistry.

[66]  B. Burchell.  Transformation Reactions: Glucuronidation , 1999 .

[67]  A. Mato,et al.  Valproic Acid for the Treatment of Myeloid Malignancies , 2008, Cancer.

[68]  A. Sandor,et al.  Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition. , 1996, Biochemical pharmacology.

[69]  K. Brouwer,et al.  Hepatobiliary disposition of valproic acid and valproate glucuronide: Use of a pharmacokinetic model to examine the rate‐limiting steps and potential sites of drug interactions , 1996, Hepatology.

[70]  H. Nau,et al.  Valproic Acid and Metabolites: Pharmacological and Toxicological Studies , 1984, Epilepsia.

[71]  R. Davis,et al.  Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. , 1994, Drugs.

[72]  I. T. de Almeida,et al.  Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. , 2001, Chemico-biological interactions.

[73]  W. Dodson,et al.  Chronic valproate administration reduces fasting ketonemia in children , 1983, Neurology.

[74]  K. Farrell,et al.  Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[75]  G. Kong,et al.  Gene expression profiles of murine fatty liver induced by the administration of valproic acid. , 2007, Toxicology and applied pharmacology.

[76]  J. Williams,et al.  Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy , 1997, European Journal of Pediatrics.

[77]  J. Raskind,et al.  The Role of Carnitine Supplementation during Valproic Acid Therapy , 2000, The Annals of pharmacotherapy.

[78]  S. Krähenbühl,et al.  Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. , 2000, Liver.

[79]  F. Chiarelli,et al.  Valproate-Induced Hyperammonemic Encephalopathy , 2002, Metabolic Brain Disease.

[80]  W. Hofmann,et al.  Fatal Liver Failure in 16 Children with Valproate Therapy , 1988, Epilepsia.

[81]  T. Baillie,et al.  Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[82]  K. Ishak,et al.  Valproate‐Induced Hepatic Injury: Analyses of 23 Fatal Cases , 2007, Hepatology.

[83]  A. Evans,et al.  Pharmacokinetics of L-Carnitine , 2003, Clinical pharmacokinetics.

[84]  E. Perucca,et al.  Pharmacological and Therapeutic Properties of Valproate , 2002, CNS drugs.

[85]  T. Kuhara,et al.  Metabolism of sodium dipropylacetate in human , 1978, European journal of drug metabolism and pharmacokinetics.

[86]  D. Norwood,et al.  Mitochondrial metabolism of valproic acid. , 1991, Biochemistry.

[87]  F. Van hoof,et al.  In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. , 1992, Biochemical pharmacology.

[88]  T. Baillie,et al.  Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[89]  G. Finocchiaro,et al.  The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. , 1990, Biochimica et biophysica acta.

[90]  W. Löscher.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. , 2002, CNS drugs.

[91]  M. Oechsner,et al.  Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency , 1998, Journal of neurology, neurosurgery, and psychiatry.

[92]  T. Baillie,et al.  Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. , 1987, Science.

[93]  T. Baillie,et al.  Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. , 1988, Chemical research in toxicology.

[94]  G. Granneman,et al.  The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic Studies , 1984, Hepatology.

[95]  W. Löscher.  Pharmacological effects and mechanisms of action , 1999 .

[96]  S. Russell.  Carnitine as an antidote for acute valproate toxicity in children , 2007, Current opinion in pediatrics.

[97]  H. Schulz,et al.  The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids. , 1994, Chemico-biological interactions.

[98]  D. Schmidt.  Adverse effects and interactions with other drugs , 1999 .

[99]  T. Baillie,et al.  Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. , 1994, Chemico-biological interactions.

[100]  I. T. de Almeida,et al.  Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. , 2001, Clinical biochemistry.

[101]  Thomas K. H. Chang,et al.  Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[102]  R. Wanders,et al.  Progressive Infantile Neurodegeneration Caused by 2-Methyl-3-Hydroxybutyryl-CoA Dehydrogenase Deficiency: A Novel Inborn Error of Branched-Chain Fatty Acid and Isoleucine Metabolism , 2000, Pediatric Research.

[103]  F. Dreifuss,et al.  Valproic acid hepatic fatalities. , 1989, Neurology.

[104]  A. Rettie,et al.  Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. , 1997, The Journal of pharmacology and experimental therapeutics.

[105]  E. Longin,et al.  Effects of Valproate on Acylcarnitines in Children with Epilepsy Using ESI‐MS/MS , 2007, Epilepsia.